Gilead Sciences Inc. said its two key hepatitis C drugs, Sovaldi
and Harvoni, generated about $4.9 billion in sales in the second
quarter, topping Wall Street estimates, thanks to
better-than-expected sales of the newer Harvoni.
For the year, the company again raised its guidance for net
product sales, this time by $1 billion, and now expects sales to
reach $29 billion to $30 billion.
Shares of Gilead, up 24% over the past year, rose 3.2% to
$116.99 in recent after-hours trading
The hepatitis C drugs represent two of the most successful drug
launches ever, marked by their high cure rates, fewer side effects
and imposing price tags.
They also have been facing competition from new hepatitis C
treatments like AbbVie Inc.'s Viekira Pak, which started sales in
December. Merck & Co. in May submitted a new drug application
for its combination treatment for hepatitis C to the U.S. Food and
Drug Administration.
During the second quarter Sovaldi sales fell to $1.29 billion, a
decline of 63% from a year earlier.
Harvoni, which combines Sovaldi with another drug and received
regulatory approval in October, had $3.61 billion in sales in its
third quarter on the market, compared with $3.58 billion in sales
in its second quarter on the market and $2.11 billion in the
previous quarter.
Analysts were expecting sales of $951 million for Sovaldi and
$3.36 billion for Harvoni, according to a note by Evercore ISI
analyst Mark Schoenebaum.
Some health plans and drug-benefit managers have complained
about the high cost of Sovaldi and Harvoni, which carry price tags
of $1,000 a day or more for certain patients. Investors likely will
be watching for signs of how discounts related to contracts with
pharmacy-benefit managers and the number of patients being treated
in the U.S. are affecting growth, according to Mr. Schoenebaum's
note.
Overall, Gilead reported a profit of $4.49 billion, or $2.92 a
share, up from $3.66 billion, or $2.20 a share, a year earlier.
Excluding expenses related to stock-based compensation,
acquisitions and restructuring, as well as other items, per-share
earnings rose to $3.15 from $2.36.
Revenue increased 26% to $8.24 billion.
Analysts polled by Thomson Reuters expected per-share profit of
$2.71 and revenue of $7.61 billion.
On Friday, AbbVie Inc. reported weaker-than-expected sales of
its new hepatitis C treatment. In addition, the FDA approved
another AbbVie hepatitis C drug, Technivie, for treatment of
patients with a subtype of the virus.
Write to Tess Stynes at tess.stynes@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires